---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-091619"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2026-08-06T11:05:29+00:00"
generated_at: "2026-08-06T11:11:49.692746+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Iovance reports record Q2 revenue ~$99M (+66% YoY); reviewing FY26 guidance; FDA FTD for lifileucel in sarcomas

## Summary
- Total product revenue ~$99M, up 66% from ~$60M in Q2 2025 and 39% from ~$71M in Q1 2026.
- U.S. Amtagvi revenue ~$91M, up 40% from Q4 2025; gross margin improved to 56%.
- Cash position ~$304M as of June 30, 2026, expected to fund operations into 2H28.
- FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (UPS/DDLPS); SARATOGA trial ORR 50% in first six patients.
- Australia TGA approved Amtagvi MAA; UK MAA resubmitted for expedited review; FY26 revenue guidance of $350-370M under review.

## SEC filing metadata
- accession: 0001104659-26-091619
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2026-08-06T11:05:29+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/0001104659-26-091619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-091619
- JSON: https://secwatch.observer/filing/0001104659-26-091619.json
- Plain text: https://secwatch.observer/filing/0001104659-26-091619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.